From theheart.org on Medscape

Coverage from the

American College of Cardiology 68th Annual Scientific Session (ACC) 2019

March 16 - 18, 2019; New Orleans, Louisiana

March 16 - 18, 2019 New Orleans, Louisiana

Booth #1911

Meeting Highlights At A Glance

  • Top News From ACC 2019: Slideshow Top News From ACC 2019: Slideshow Standing-ovation worthy research on transcatheter aortic valve replacement (TAVR) in low-surgical-risk patients featured prominently at this year's scientific session.

Conference News

© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Perspectives From ACC

 

Bloggers from the Floor

  • Taking the Pulse of the Apple Heart Study What did we really learn from the study using a smart watch and phone app to identify atrial fibrillation? New ways to conduct research, but not much to advance practice, argues John Mandrola, MD.
  • A Sobering Breakthrough in AF Care Frequent alcohol drinkers with atrial fibrillation benefitted from abstinence in a novel randomized trial, which prompts the question: Should temperance be prescribed before meds and procedures?
  • Boom: TAVR Low-Risk Trials Usher in a New Era in Cardiology The results are impressive for transcatheter aortic valve replacement in low-surgical-risk patients, but longer-term data on durability will be crucial, notes John Mandrola, MD.
  • Quick Thoughts on the Wrap-IT Trial An antibiotic-impregnated envelope casing for cardiac implantable devices may lower the risk for infection, but is it enough to justify the costs?
  • What's New and Useful in Hypertension From ACC.19 Melissa Walton-Shirley's takeaways on hypertension management, a topic close to her heart, from the latest studies and expert presentations at the 2019 American College of Cardiology Scientific Session.
  • Burnout: Is the Red Tide Finally Beginning to Turn? Burned out listening to burn-out talks? An intense session at ACC.19 left Melissa Walton-Shirley, MD, hopeful that some of those words would finally turn into action.
 
 

Popular News from ACC 2018

  • ODYSSEY: Alirocumab Cuts CV Events, All-Cause Death Post-ACS ODYSSEY: Alirocumab Cuts CV Events, All-Cause Death Post-ACS First evidence of survival benefit with PCSK9 inhibitor alirocumab reignites the call for greater access to these expensive drugs for patients not just with ACS but also with stable atherosclerotic CVD.
  • VEST: No Sudden Death Benefit Early Post-MI From LifeVest VEST: No Sudden Death Benefit Early Post-MI From LifeVest But defibrillators work by preventing sudden death, so it's a bit of a head-scratcher that all-cause mortality dropped instead for people who used the wearable defibrillator for 90 days after their MI.
  • Barbershop-Based Healthcare Cuts Hypertension in Blacks Barbershop-Based Healthcare Cuts Hypertension in Blacks An outreach program leveraging the community barbershop made impressive inroads combatting hypertension in black men, who have the highest hypertension-related death rate in the United States.

Previous Coverage